Results 101 to 110 of about 37,365 (212)

Mechanisms of XCR1 Membrane Trafficking and Constitutive Endocytosis [PDF]

open access: yesBasic Clin Pharmacol Toxicol
ABSTRACT Chemokines orchestrate immune cell trafficking through receptor‐mediated signalling and are implicated in inflammatory, autoimmune and neuropathic disorders. The XCL1–XCR1 axis is of particular interest because XCR1 is selectively expressed on mature conventional type 1 dendritic cells (cDC1s), where it supports communication with activated ...
Li Q   +3 more
europepmc   +2 more sources

SARS‐CoV‐2 targets mitochondria, exacerbating COVID‐19 pneumonia

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Following entry into airway epithelial cells (AECs), SARS‐CoV‐2 releases its single‐stranded RNA into the cytoplasm, where it is translated into viral proteins. Several of these viral proteins localize to mitochondria and interact with key mitochondrial components.
Danchen Wu   +5 more
wiley   +1 more source

Warburg redefined: Metabolites, mitochondria and macrophages in immune regulation

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Following pro‐inflammatory stimulation, macrophages undergo Warburg‐like metabolic rewiring that extends more than increased glycolysis. The non‐canonical functions of glycolytic enzymes and lactate accumulation control macrophage immune responses through multiple signalling pathways (a).
Yukun Min   +2 more
wiley   +1 more source

Complexity of Clathrin Coat Dynamics in Endocytosis

open access: yesTraffic, Volume 27, Issue 4, December 2026.
Clathrin dynamics during endocytosis. Dynamic exchange of clathrin triskelia and other endocytic proteins may be critical for several processes taking place during the maturation of endocytic vesicles. ABSTRACT Clathrin‐mediated endocytosis is a process by which eukaryotic cells internalise a wide range of molecules such as signalling factors ...
Anne‐Laure Boinet   +2 more
wiley   +1 more source

Cholesterol Biomimetic Fluorescent Probe for the High Signal‐to‐Noise Ratio and Selectivity Imaging of Nonalcoholic Fatty Liver

open access: yesAggregate, Volume 7, Issue 11, November 2026.
A cholesterol‐biomimetic AIE probe, TPAS‐PyCHO+, was designed and synthesized for selective imaging of nonalcoholic fatty liver. The probe hijacked NPC1L1‐mediated clathrin‐dependent endocytosis in steatotic hepatocytes, selectively accumulated in lipid droplets, and enabled high signal‐to‐noise ratio imaging of NAFLD in mice.
Kunyi Wang   +7 more
wiley   +1 more source

Refining Domain‐Based Prognostication in DNM1 Encephalopathy: A Mild Phenotype Associated With a GTPase Domain Variant

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 11, Page 2558-2561, November 2026.
ABSTRACT DNM1 encephalopathy is a rare autosomal dominant genetic condition characterized by a range of neurological and developmental manifestations. The typical phenotype is severe, including profound intellectual disability, treatment‐resistant epilepsy, ataxia, and structural brain abnormalities. However, milder presentations have increasingly been
Caroline Crain   +6 more
wiley   +1 more source

High Level of Component C1q Binding Protein (C1QBP) is Associated With Poor Prognosis and Dysfunction of Mast Cells in Lung Adenocarcinoma

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Component C1q binding protein (C1QBP) is known as an important regulator of mitochondrial plasticity and is involved in antitumor immune response in cancers. Nevertheless, its role in lung adenocarcinoma (LUAD) still remains largely unknown.
Wei Li   +9 more
wiley   +1 more source

Beneficial Role of Natural Polyphenols Against Epilepsy: Greasing the Wheels of Pharmacotherapy Research for Epilepsy

open access: yesFood Frontiers, Volume 7, Issue 6, November 2026.
ABSTRACT Epilepsy is the most disabling neurological disease that affects all economic classes, age groups, regions, and races. Although many antiseizure drugs are approved for epilepsy treatment, they fail to work in about 30%–40% of patients. Thus, there is a great need to identify better pharmacological agents to treat epilepsy.
Janakiraman Pillai Udaiyappan   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy